Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
TEM Forecast Markets
Tempus AI, Inc.
7
Active Markets
50%
Avg Probability
All Markets
7 markets
Will Tempus AI report FY2026 revenue at or above $1.59B guidance?
78%
Likely Yes
85% agreement
Mar 15, 2027
IG: 0.00
Will Tempus migrate majority (>50%) of xT CDx volume to FDA-approved version by Q4 2026?
65%
Likely Yes
78% agreement
Mar 15, 2027
IG: 0.00
Will the TEM securities class action (AI-washing) survive the motion to dismiss by December 31, 2026?
35%
Likely No
72% agreement
Jan 15, 2027
IG: 0.00
Will Tempus receive MolDX coverage for its CRC MRD assay by September 30, 2026?
52%
Likely Yes
68% agreement
Oct 15, 2026
IG: 0.00
Will Tempus AI report FY2026 adjusted EBITDA at or above $65M guidance?
72%
Likely Yes
80% agreement
Mar 15, 2027
IG: 0.00
Will Tempus report any single quarter of FY2026 with AI algorithm/application revenue exceeding $50M?
8%
Likely No
92% agreement
Mar 15, 2027
IG: 0.00
Will Tempus report average genomics ASP above $1,800 for any quarter in H1 2026?
38%
Likely No
75% agreement
Sep 15, 2026
IG: 0.00
Resolution Timeline
Sep 15, 2026
Will Tempus report average genomics ASP above $1,800 for any quarter in H1 2026?Prediction: 38%
Oct 15, 2026
Will Tempus receive MolDX coverage for its CRC MRD assay by September 30, 2026?Prediction: 52%
Jan 15, 2027
Will the TEM securities class action (AI-washing) survive the motion to dismiss by December 31, 2026?Prediction: 35%
Mar 15, 2027
Will Tempus migrate majority (>50%) of xT CDx volume to FDA-approved version by Q4 2026?Prediction: 65%
Mar 15, 2027
Will Tempus report any single quarter of FY2026 with AI algorithm/application revenue exceeding $50M?Prediction: 8%